REC-1245

REC-1245 is a protein degrader (small molecule) from Recursion Pharmaceuticals. A highly potent RBM39 degrader; the company describes RBM39 as a DNA damage response target whose loss mimics CDK12 loss. Its furthest stage is phase 1, for solid tumours and lymphoma. ClinicalTrials.gov registers it in one study linked below. Pipeline page: 'Status: Phase 1'; phase 1 DAHLIA study ongoing. Registry NCT06678659 (phase 1/2) recruiting. Whether it works in people has not been established unless a trial below reports it.